425 related articles for article (PubMed ID: 27082583)
21. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
[TBL] [Abstract][Full Text] [Related]
22. [Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
Tian WY; Wang YM; Yan Y; Gao JP; Sun DD; Jiang S; Sheng Y; Teng F; Xue FX
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):810-817. PubMed ID: 27916063
[No Abstract] [Full Text] [Related]
23. Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center.
Tai YJ; Hsu HC; Chiang YC; Chen YL; Chen CA; Cheng WF
Int J Environ Res Public Health; 2019 Jul; 16(14):. PubMed ID: 31323767
[TBL] [Abstract][Full Text] [Related]
24. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
25. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification.
Werner HM; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; Amant F; Salvesen HB;
Gynecol Oncol; 2012 Apr; 125(1):103-8. PubMed ID: 22100838
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
27. Lymphadenectomy and prognosis for elderly females with stage I endometrioid endometrial cancer.
Zhao L; Li L; Ye Y; Han X; Fu X; Yu Y; Luo J
Arch Gynecol Obstet; 2019 Sep; 300(3):683-691. PubMed ID: 31256231
[TBL] [Abstract][Full Text] [Related]
28. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology.
Chi DS; Barakat RR; Palayekar MJ; Levine DA; Sonoda Y; Alektiar K; Brown CL; Abu-Rustum NR
Int J Gynecol Cancer; 2008; 18(2):269-73. PubMed ID: 18334008
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Chemotherapy versus Radiotherapy in High-risk, Early-stage Endometrioid Endometrial Carcinoma.
Wu M; Yang YN; Huang YH; Cai J; He XQ; Wang ZH
Curr Med Sci; 2022 Feb; 42(1):185-191. PubMed ID: 34669113
[TBL] [Abstract][Full Text] [Related]
30. Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian study.
Uccella S; Falcone F; Greggi S; Fanfani F; De Iaco P; Corrado G; Ceccaroni M; Mandato VD; Bogliolo S; Casarin J; Monterossi G; Pinelli C; Mangili G; Cormio G; Roviglione G; Bergamini A; Pesci A; Frigerio L; Uccella S; Vizza E; Scambia G; Ghezzi F
J Gynecol Oncol; 2018 Nov; 29(6):e100. PubMed ID: 30207108
[TBL] [Abstract][Full Text] [Related]
31. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival.
Bristow RE; Zahurak ML; Alexander CJ; Zellars RC; Montz FJ
Int J Gynecol Cancer; 2003; 13(5):664-72. PubMed ID: 14675352
[TBL] [Abstract][Full Text] [Related]
32. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
33. Histopathological prognostic factors predicting para-aortic lymph node metastasis in patients with endometrioid uterine cancer.
Karube Y; Fujimoto T; Takahashi O; Nanjyo H; Mizunuma H; Yaegashi N; Sugiyama T; Kurachi H; Sato A; Tanaka T
Gynecol Oncol; 2010 Aug; 118(2):151-4. PubMed ID: 20621776
[TBL] [Abstract][Full Text] [Related]
34. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment.
Barlin JN; Soslow RA; Lutz M; Zhou QC; St Clair CM; Leitao MM; Iasonos A; Hensley ML; Barakat RR; Matias-Guiu X; Abu-Rustum NR
Int J Gynecol Cancer; 2013 Nov; 23(9):1620-8. PubMed ID: 24126219
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy.
Bakkum-Gamez JN; Mariani A; Dowdy SC; Weaver AL; McGree ME; Martin JR; Keeney GL; Jatoi A; Gostout BS; Podratz KC
Gynecol Oncol; 2014 Mar; 132(3):578-84. PubMed ID: 24434057
[TBL] [Abstract][Full Text] [Related]
36. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
[TBL] [Abstract][Full Text] [Related]
37. SATEN III-Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study.
Kahramanoglu I; Meydanli MM; Taranenka S; Ayhan A; Salman C; Sanci M; Demirkiran F; Ortac F; Haidopoulos D; Sukhin V; Kaidarova D; Stepanyan A; Farazaneh F; Aliyev S; Ulrikh E; Kurdiani D; Yalcin İ; Mavrichev S; Akilli H; Sarı ME; Pletnev A; Aslan K; Bese T; Kairbayev M; Vlachos D; Gultekin M
Int J Gynecol Cancer; 2019 Oct; 29(8):1271-1279. PubMed ID: 31481453
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study-On behalf of the Swedish Gynecological Cancer Group.
Stålberg K; Kjølhede P; Bjurberg M; Borgfeldt C; Dahm-Kähler P; Falconer H; Holmberg E; Staf C; Tholander B; Åvall-Lundqvist E; Rosenberg P; Högberg T
Int J Cancer; 2017 Jun; 140(12):2693-2700. PubMed ID: 28340503
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
